EGFR frequently exhibits overexpression or mutations across various malignancies, including HCC, non-small cell lung cancer, breast carcinoma, pancreatic adenocarcinoma, nasopharyngeal carcinoma, and head and neck squamous cell carcinoma [26–29]. This evidence concerns the gene EGFR and pancreatic adenocarcinoma.